Site Search
Results
-
ICCVAM Biennial Progress Report 2022-2023
... Safety testing strategy for cell-based human cancer therapies Tags: NCI, stem cells Preclinical safety assessment for chimeric antigen receptor (CAR) T cell-based therapies is ...
Size: 995KB https://ntp.niehs.nih.gov/sites/default/files/2024-09/2022-2023_ICCVAMBienRpt_FD_508.pdf -
Monograph: Helicobacter pylori; May 2018
... or policy. 11 Many different therapies are used in the United States, but the ... OR intervention*[tiab] OR therapies[tiab] OR Therapy[tiab] OR ...
Size: 692KB https://ntp.niehs.nih.gov/sites/default/files/ntp/roc/draftmono/hpyloridraftmonograph_508.pdf -
Monograph: Helicobacter pylori; September 2018
... Many different therapies are used in the United States, but the American College of ... OR intervention*[tiab] OR therapies[tiab] OR Therapy[tiab] OR ...
Size: 734KB https://ntp.niehs.nih.gov/sites/default/files/ntp/roc/draftmono/hpyloridraftmonographrevised_508.pdf -
GMM-16: Genetically Modified Model Report on Study of Mixtures...
... Meta- bolic complications of HAART therapies include vas- cular necrosis, decreased bone ... Hematologic effects of AIDS therapies. Hematol. Oncol. Clin. North Am. 5, 229-248. Plumb, ...
Size: 5.4MB https://ntp.niehs.nih.gov/go/gmm16 -
RoC Monograph: Epstein-Barr Virus; August 2016
... such as anti-rejection therapies or congenital immunodeficiency (Carbone et al. 2008). ... EBV-related non-Hodgkin lymphomas have been linked to immunosuppression therapies related ...
Size: 2.0MB https://ntp.niehs.nih.gov/go/rocmgraph07 -
RoC Monograph: Human Immunodeficiency Virus Type 1; August 2016
... are called highly active antiretroviral therapies (HAART) or combination antiretroviral ... However, the availability of antiretroviral therapies, particularly the new generation of ...
Size: 2.2MB https://ntp.niehs.nih.gov/go/rocmgraph08 -
TR-578: Ginkgo Biloba Extract (CASRN 90045-36-6) in F344/N Rats...
... cases of spontaneous bleeding associated with Ginkgo biloba extract through 2007, with one third of the cases involving concurrent use of antiplatelet or anticoagulant therapies. ...
Size: 4.1MB https://ntp.niehs.nih.gov/go/tr578 -
ICCVAM Biennial Progress Report 2020-2021
... and adoption of human MPS for testing therapies and improving disease understanding. ... to apply MPS to the development of therapies for COVID-19. Activities of the MPSCoRe ...
Size: 940KB https://ntp.niehs.nih.gov/iccvamreport/2021 -
RoC Background Document: Chlorozotocin (CZT); Nov. 18-19, 1996
... relative risk, 12.4; 95% confidence interval, 1.7- 250) among 2067 patients treated with methyl-CCNU. Only 1 case was observed among 1566 patients treated with other therapies. ...
Size: 1.6MB https://ntp.niehs.nih.gov/sites/default/files/ntp/newhomeroc/other_background/chlorozotocin1_508be.pdf -
RoC Background Document: Chloramphenicol; Dec. 13-14, 2000
... transplantation and immunosuppressive therapies, has improved the prognosis for these 11 ... Although it is possible that certain therapies may contribute to the development of MDS/...
Size: 751KB https://ntp.niehs.nih.gov/sites/default/files/ntp/newhomeroc/roc10/chl_no_appendices_508.pdf
to Top